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A substantial proportion of colorectal cancers (CRCs) are interval CRCs (I-CRCs; i.e., CRCs diagnosed soon after a
colonoscopy). Chromosomal instability (CIN) is defined as an increase in the rate of which whole chromosomes/
large chromosomal fragments are gained or lost and is observed in 85% of non-hereditary CRCs. The contribution
of CIN to the etiology of I-CRCs remains unknown. We established a fluorescence in situ hybridization (FISH)
approach to characterize CIN by enumerating specific chromosomes and determined the prevalence of numerical
CIN in a population-based cohort of I-CRCs and control (sporadic) CRCs. Using the population-based Manitoba
Health administrative databases and Manitoba Cancer Registry, we identified an age, sex, and colonic site of CRC
matched cohort of I-CRCs and controls and retrieved their archived paraffin-embedded tumor samples. FISH
chromosome enumeration probes specifically recognizing the pericentric regions of chromosomes 8, 11, and 17
were first used on cell lines and then CRC tissue microarrays to detect aneusomy, which was then used to
calculate a CIN score (CS). The 15th percentile CS for control CRC was used to define CIN phenotype. Mean CSs
were similar in the control CRCs and I-CRCs; 82% of I-CRCs exhibited a CIN phenotype, which was similar to that
in the control CRCs. This study suggests that CIN is the most prevalent contributor to genomic instability in I-
CRCs. Further studies should evaluate CIN and microsatellite instability (MSI) in the same cohort of I-CRCs to
corroborate our findings and to further assess concomitant contribution of CIN and MSI to I-CRCs.
Neoplasia (2015) 17, 306–316(Winnipeg, Canada) funded in part by the CancerCare Manitoba Foundation and
Canadian Institutes of Health Research. We acknowledge the strong support of the
Research Institute of Oncology and Hematology and CancerCare Manitoba
Foundation. The results and conclusions are those of the authors, and no official
endorsement by Manitoba Health is intended or should be inferred.
2This article refers to supplementarymaterials, which are designated by Supplementary Tables 1
to 5 and Supplementary Figures 1 to 3 and are available online at www.neoplasia.com.
Received 26 November 2014; Revised 29 January 2015; Accepted 4 February 2015
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1476-5586/15
http://dx.doi.org/10.1016/j.neo.2015.02.001
Neoplasia Vol. 17, No. 3, 2015 Prevalence of Chromosome Instability Cisyk et al. 307Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related
deaths in North America, with more than 80% of these tumors
arising randomly (i.e., without family history of affected first-degree
relatives and/or predisposing hereditary syndromes), emphasizing the
need for accurate screening and diagnostic strategies [1–3].
Colonoscopy is an accepted CRC screening test as it has been
shown in observational studies to reduce CRC incidence and
mortality by identifying CRCs at earlier stages as well as CRC
precursor lesions (i.e., polyps) [2,4]. Furthermore, even when other
approaches are used as the initial CRC screening test, colonoscopy is
employed to investigate the positive results and diagnose CRC, and
thus, most CRCs are now diagnosed on colonoscopy. However, even
with colonoscopies, there remain a proportion of CRCs, termed
interval CRCs (I-CRCs), that are diagnosed within a relatively short
time period after a negative colonoscopy (i.e., colonoscopy that did
not detect CRC). A recent meta-analysis estimated that approxi-
mately 1 in 27 CRCs is I-CRC [5], and if extrapolated to the statistics
provided by the American Cancer Society, approximately 5200
Americans will be diagnosed with an I-CRC in 2014, and nearly 2000
will succumb to the disease [6]. Whether these tumors are missed
sporadic CRCs that arise due to false-negative colonoscopies [7–13]
or are a distinct subtype of CRC that harbor unique biologic
properties [7,11,14–17] that result in rapidly developing tumors is
currently unknown (reviewed in [18]).
Genome instability is a hallmark of virtually all tumor types and is
arguably best described in CRC. In general, genome instability arises
through one of three aberrant pathways: microsatellite instability
(MSI), CpG island methylator phenotype (CIMP), or chromosomal
instability (CIN) [1,19,20]. MSI arises due to defects in the DNA
mismatch repair pathway [21] that result in subtle genomic
alterations, while CIMP is an epigenetic phenomenon associated
with DNA methylation and gene silencing [22]. CIN is defined as an
increase in the rate at which whole chromosomes, or large parts
thereof, are gained or lost, and thus, aneuploidy is often employed as a
metric for CIN [23]. Within traditional sporadic CRC, MSI and CIN
are generally accepted to be mutually exclusive pathways [23,24],
while it has been proposed that CIMP may contribute to the
development of MSI and/or CIN [25].
Currently, very little is known about the aberrant etiological origins
of I-CRCs. Three studies have only examined the prevalence of the
MSI [15,17] and CIMP [14,17] pathways within two distinct patient
cohorts, and CIN has yet to be evaluated. Nevertheless, these studies
demonstrated that I-CRCs do exhibit distinct biology relative to their
traditional sporadic CRC counterparts. In fact, these studies revealed
a 3.0- and 1.5-fold increase in the prevalence of MSI and CIMP,
respectively, within I-CRCs relative to sporadic CRCs. Given the
general observation that MSI and CIN are mutually exclusive, these
results suggest that the prevalence of CIN within I-CRCs should be
reduced. However, the prevalence of CIN is currently unknown in
I-CRCs, and thus, it is critical to characterize its potential
contribution to the pathogenesis of these tumors.
In this study, we established and employed a fluorescence in situ
hybridization (FISH)–based approach to evaluate numerical CIN
within a Manitoban cohort of I-CRCs and sporadic CRCs.
Aneusomy (i.e., abnormal chromosome numbers) was used as the
metric for CIN, and through chromosome enumeration within
patient-derived tumor samples, we identified the extent of CIN
within I-CRCs to be nearly identical to that of the matched control/sporadic CRCs. More specifically, the chromosome enumeration
results showed no statistically significant differences between the
interval and sporadic cohorts for each subcategory (i.e., gender, age,
tumor location, and so on). Our data show that CIN is frequently
observed in I-CRCs and further suggest that it likely contributes to
the development of these tumors. Finally, due to the similar CIN
profiles observed in both I-CRCs and sporadic CRCs, our findings
suggest that missed sporadic CRCs may be a predominant factor in
the development of I-CRCs.Materials and Methods
Ethics Statement
This study, including the collection and use of archived clinical
CRC tissue samples, was approved by the University of Manitoba
Research Ethics Board and Pathology Access Committee for Tissue
and Manitoba’s Health Information Privacy Committee.
Cell Culture
HeLa cells were purchased from American Type Culture Collection
(Manassas, VA) and are a hypotetraploid cervical adenocarcinoma cell
line with a modal number of 82 chromosomes, while hTERT cells are a
diploid, immortalized fibroblast cell line with a modal number of
46 chromosomes [26] that were generously provided by Dr C. P. Case
(Bristol University, Bristol, United Kingdom). Cells were grown in
Dulbecco's modified Eagle's medium (HyClone) supplemented with
10% FBS at 37°C in a humidified incubator with 5% CO2.
Patient Identification
Manitoba Health is the publicly funded health insurance agency
that provides health care coverage to all Manitoba residents.
Manitoba Health maintains a number of electronic databases,
including hospital discharge and physician claims, for monitoring
and accounting purposes [27]. Every resident of Manitoba is assigned
a unique personal health identification number, which can be used to
link patient records longitudinally. For the current study, CRCs
occurring in Winnipeg residents (the largest provincial city with two
thirds of the Manitoba residents) were identified from the
population-based Manitoba Cancer Registry (which tracks all cancers
diagnosed in the province) and linked to patient colonoscopy records
through Manitoba Health databases to identify I-CRCs and control
CRCs. Medical records of colonoscopies were reviewed to determine
the differences in colonoscopies in the two groups.
CRC Cohort
For the purpose of this study, I-CRCs were defined as CRCs
diagnosed between 6 and 36 months following a colonoscopy, while
CRCs detected on initial colonoscopy (on the date of the colonoscopy
or within a month thereafter) were classified as sporadic and were
included as controls. Sporadic CRCs were matched 2:1 to I-CRC by
age (±5 years), gender, and tumor location in the colon (i.e., right vs
left). CRCs occurring in and proximal to the splenic flexure were
considered right-sided CRC and those more distally left-sided CRC.
Only CRCs diagnosed between 1 January 2007 and 30 March 2010
were included. Exclusion criteria included patients with prior CRC or
inflammatory bowel disease, as well as patients diagnosed with CRC
before the age of 50 years, due to the higher probability of a hereditary
predisposition for CRC.
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were supplied by the Department of Pathology serving all six hospitals in
the city of Winnipeg. Samples were provided in an anonymized,
double-blinded fashion and the I-CRC status was only revealed once all
samples had been analyzed. A total of 141 samples including 46 I-CRCs
and 95 sporadic (control) CRCs was obtained and evaluated for CIN.
CRC Tissue Microarray
CRC samples were provided as archived clinical formalin-fixed,
paraffin-embedded tissue blocks with corresponding hematoxylin and
eosin–stained slides. Slides were examined by a pathologist (R.H.W.,
University ofManitoba), and tumor regions distal to tumor borders and
necrotic zones were identified and used to generate six tissuemicroarrays
(TMAs). The TMAs were generated by theManitoba Tumor Bank and
housed 21 to 32 unique patient tumor samples cored (0.6 mm) in
duplicate, with mouse tissues included for orientation purposes. TMAs
were sectioned at 5 μm and subjected to FISH as detailed below.
Fluorescence In Situ Hybridization
FISH chromosome enumeration probes (CEPs) specifically
recognizing the pericentric regions of chromosomes 8 (CEP8;
SpectrumOrange), 11 (CEP11; SpectrumGreen), and 17 (CEP17;
SpectrumAqua) were purchased from Vysis (Abbott Molecular Inc.,
Mississauga, Ontario, Canada). Chromosomes 8, 11, and 17 were
specifically selected for evaluation purposes, as genes encoded within
these chromosomes have been found altered in CRCs and/or are
thought to play a role in CRC tumorigenesis, including MYC and
fibroblast growth factor receptor 1 (chromosome 8), ataxia
telangiectasia mutated and MRE11 meiotic recombination 11
homolog A (chromosome 11), and tumor protein p53 (chromosome
17) [28–32]. Furthermore, pericentric CEPs were employed as the
centromere is an essential chromosomal element that is normally
required for mitotic fidelity and thus chromosome stability. FISH was
performed first on cell lines according to the manufacturer (Vysis) to
confirm and validate specificity. In brief, pepsin-treated samples were
rinsed in phosphate-buffered saline and dehydrated in an ethanol
series (70%, 90%, and 100%) and allowed to air dry. DNA was
denatured by heating (70°C for 5 minutes) and transferred to 70%
formamide/2× SSC at 70°C (2 minutes) before ethanol fixation. A
multiplexed CEP cocktail was prepared by combining CEP11 and
CEP17 to the pre-diluted CEP8. The CEP8/11/17 cocktail was
transferred to a coverslip and subsequently applied to the samples on
the denatured slide. Samples were incubated in the ThermoBrite slide
processing system at 77°C (10 minutes), followed by 37°C overnight.
Following CEP labeling, cells were counterstained with 4’,6-
diamidino-2-phenylindole (DAPI) andmounted in Vectashield anti-fade
reagent (Vector Laboratories, Burlingame, CA) before manually
evaluating the position, chromosome, and number of each CEP probe
within mitotic spreads from both cell lines. CEP foci were manually
enumerated within interphase nuclei to confirm their ability to accurately
reflect the expected number of CEP signals (i.e., chromosomes).
TMAs were processed for FISH using a standard FISH protocol.
Briefly, tissue sections were deparaffinized through two washes in xylene
(6 minutes each) and ethanol (100%; 10minutes each) and allowed to air
dry. Sampleswere incubated in citric acid buffer at 80°C (1 hour), followed
by pepsin treatment (0.5mg/ml) for 45minutes. TMAswere rinsed (twice
in 2× SSC) and dehydrated (ethanol series), before incubation with the
multiplexed CEP probes as above. Excess CEPs were removed with three
washes in 50% formamide/2× SSC (46°C; 10 minutes each), followed by2× SSC (46°C; 10minutes) and 2× SSC/0.1%NP-40 (46°C; 5minutes).
Finally, sampleswerewashedwith2×SSC (roomtemperature; 5minutes),
counterstainedwithDAPI,mounted inVectashield, and stored in the dark
at −20°C until imaged.
Image Acquisition and Deconvolution
For tissue culture cells, two-dimensional images were acquired using an
Axioplan 2 (Zeiss) equipped with a 63× Plan-Apochromat oil-immersion
objective (numerical aperture 1.40). Images were analyzed using the Case
Data Manager software from Applied Spectral Imaging (Carlsbad, CA).
The identification of the individual chromosomes (i.e., karyotyping) was
automated and based on the inverted DAPI staining pattern. For TMA
imaging and to preserve CEP signal intensities and ensure that samples
could be imaged immediately following hybridization, six mini-TMAs,
harboring 19 to 32 unique patient samples were arrayed in duplicate to
address reproducibility. Three-dimensional (3D) images were acquired
with an AxioImager Z1 microscope (Zeiss, Toronto, Ontario, Canada)
equipped with an AxioCam HR charge-coupled device camera (Zeiss)
and 40 Plan-Neofluar (numerical aperture 1.30) and 63× Plan-
Apochromat (numerical aperture 1.40) lenses. Approximately four to
eight nonoverlapping 3D image series were acquired from each core at
0.4-μm intervals, and images were collected usingDAPI, cyan fluorescent
protein (SpectrumAqua), fluorescein isothiocyanate (SpectrumGreen),
and Cy3 (SpectrumOrange) filter sets. 3D data sets were processed by
maximum-likelihood expectation deconvolution in AutoQuant X3
(Media Cybernetics) using a constrained iterative algorithm and a
theoretical point spread function for each fluorescent channel: DAPI
(461 nm), cyan fluorescent protein (476 nm), fluorescein isothiocyanate
(525 nm), and Cy3 (570 nm). Each 16-bit image was imported into
Imaris v7.7.1 (Bitplane) image visualization software, where CEP8/11/17
was enumerated (see CEP Evaluation section).
CEP Evaluation
3D deconvolved images were imported into Imaris where CEP8/11/17
was manually enumerated from 100 nuclei per core whenever possible.
Briefly, the DAPI channel was used to generate a surface rendering
(Supplementary Figure 1) to ensure that only intact (i.e., complete) nuclei
were included in the analysis, and only the CEP8/11/17 foci contained
within intact nuclei were evaluated. CEP8/11/17 foci were enumerated if
1) it was containedwithin the nuclear volume as defined byDAPI staining,
2) it was a distinct signal that did not colocalize with any of the remaining
CEP channels and therefore is unlikely to be tissue autofluorescence or
channel bleed-through, 3) it was spheroid in shape, and 4) it exhibited a
similar signal intensity to the other CEP foci within the particular channel
and image. All figures and panels were generated in Photoshop CS6.
CIN Analyses
The CIN score (CS) is a metric devised to describe both the gains and
losses of CEP foci within a given patient sample. It was calculated for each
individual CEP [e.g., CS for chromosomes 8, 11, or 17 within a nucleus
or sample (CS8, CS11, or CS17, respectively)] and for all three CEPs
combined (CSC) for each nucleus evaluated. A CEP-specific CS (e.g.,
CS8) is calculated for a given nucleus using the following formula: [CS8 =
|eChr8 - oChr8|], where CS equals the absolute value obtained when the
observed (o) number of CEP8 foci is subtracted from the expected (e)
number of two CEP8 foci (expect 1 focus/chromosome × 2 copies/cell).
By summing the values for a given patient sample and dividing by the
number of nuclei evaluated, the CS8 for that sample is calculated. The
corresponding CSC for a given nucleus is calculated by summing each of
Figure 1. Evaluating the specificity and efficacy of CEP8/11/17. (A) A representative mitotic spread depicting the localization pattern of
CEP8 (red), CEP11 (green), and CEP17 (yellow) obtained from diploid, hTERT cells. (B) Karyotypic analysis of the mitotic chromosome
spread presented in A demonstrating the specificity of CEP8/11/17 for their respective chromosomes. Each CEP hybridizes with high
specificity to the pericentric regions of the corresponding chromosome and presents as two copies (foci) per CEP (one focus per
chromosome). (C) Representative images acquired from a mitotic chromosome spread (top) and interphase hTERT cells (bottom)
hybridized with CEP8/11/17. Note that each CEP presents as two foci within each interphase nucleus and indicates the presence of two
copies of the corresponding chromosome. (D) Representative images acquired from a mitotic chromosome spread (top) and interphase
hypotetraploid HeLa cells (bottom) hybridized with CEP8/11/17. Note that four, three, and three copies of CEP8, CEP11, and CEP17,
respectively, are observed in both the mitotic spread and interphase cells.
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an overall meanCS can be calculated for each patient sample by summing
the CSC for each nucleus analyzed within a patient sample and dividing by
the total number of nuclei evaluated:
CS ¼ 1
n
Xn
i¼1
e8−o8j j þ e11−o11j j þ e17−o17j jð Þi
where n is the number of nuclei evaluated in the sample. By definition,
CSC = 0 indicates that the nucleus is diploid. However, for the purpose of
this study, we operationally defined the 15th percentile of the CS for the
sporadic CRCs (1.68) as the minimum threshold for a CIN phenotype,based on the general observation that 15% of sporadic CRCs exhibit MSI
phenotype while 85% harbor a CIN phenotype [21,23,33]. All data were
imported to Prism (GraphPad, version 6.0a), where scatterplots and bar
graphs were generated.
Statistical Analysis
Standard statistical analyses were performed and include Student’s t
tests to compare ages, while Fisher tests were used to compare sex
distribution and grade. Tumor, metastases, nodes status was compared
using exact Mantel-Haenszel test. Median test with linearity was
performed to assess if there was an increasing trend ofCS values above
the median, when assessing from proximal to distal colonic site cancers.
310 Prevalence of Chromosome Instability Cisyk et al. Neoplasia Vol. 17, No. 3, 2015The Spearman rank correlation test was used to assess correlation ofCS
values with age. Missing data were omitted from the analyses. We had
estimated that with a sample size of 50 I-CRCs and 100 control CRCs we
would have an 80%chance to detect a true difference in themean number
of chromosomes in the matched pairs of ± 1.954 with a probability of
0.05 and were limited by slightly smaller number of retrievable samples.
Results
Establishing the Specificity of the CEP FISH Probes
Before enumerating chromosomes within the TMAs, we first sought to
confirm the specificity of theFISHprobes and assess their ability to accurately
enumerate chromosomes usingwell-defined, cell-basedmodels that included
bothdiploid (hTERT) andhypotetraploid (HeLa) cells. Accordingly,mitotic
chromosome spreads were generated fromhTERT cells and hybridized with
CEP8/11/17. Fluorescence images were collected, and karyotypic analyses
were conducted (Figure 1). Figure 1B demonstrates that each of the CEPs
correctly recognized the pericentric regions from the corresponding pair of
cognate chromosomes with high specificity. Having confirmed the CEP
specificities in mitotic chromosome spreads, we next sought to evaluate the
ability of CEP8/11/17 to enumerate chromosomes within interphase
hTERT nuclei, as the CRC tumor samples are composed almost exclusively
of interphase cells. To accomplish this, asynchronous cells were fixed,Table 1. Comparison of I-CRC and Sporadic CRC Study Subjects and Tumor Characteristics
Sporadic CRC (N * = 95) I-CRC (N = 46
n † (%) n (%)
Subject
Age, mean ± SD (years) 70.1 ± 8.0 70.7 ± 7.9
Sex
Male 64 (67.4) 29 (63.0)
Female 31 (32.6) 17 (37.0)
Sample
Location
Proximal 70 (73.7) 35 (76.1)
Distal 25 (26.3) 11 (23.9)
TNM stage
0 0 1 (2.2)
1 11 (11.6) 6 (13.0)
2 35 (36.8) 15 (32.6)
3 28 (29.5) 15 (32.6)
4 20 (21.1) 9 (19.6)
N/D § 1 (1.1) 0
TNM stage (clustered)
1 and 2 46 (48.9) 21 (46.7)
3 and 4 48 (51.1) 24 (53.3)
Grade
1 8 (8.4) 3 (6.5)
2 67 (70.5) 30 (65.2)
3 13 (13.7) 8 (17.4)
4 1 (1.1) 0
N/D 6 (6.3) 5 (10.9)
Grade (clustered)
1 and 2 75 (84.3) 33 (80.5)
3 and 4 14 (15.7) 8 (19.5)
Index colonoscopy b
Completed to caecum# 54 (84) 33 (79)
Speciality of physician performing colonoscopy
Gastroenterology 34 (40) 9 (21)
Surgery 52 (60) 33 (79)
* N = total number of samples in the cohort.
† n = number of samples in sub-category.
‡ P value b .05 is statistically significant.
§ N/D = not determined.
b Index colonoscopy = medical records could not be retrieved for all cases. The proportions reported for inde
non-gastroenterology, non-surgical specialities was very few and those numbers are not broken down further to
# Completed to caecum = excluding colonoscopies with obstructing lesions.hybridized with CEP8/11/17, and imaged (Figure 1C). In agreement with
the above findings, each probe produced two distinct foci within each
interphase nucleus and thus confirmed the ability of each CEP to accurately
enumerate their respective chromosomes within interphase cells.
Intuitively, increases or decreases in chromosome numbers will be
reflected by corresponding gains or losses in CEP foci, respectively. To
formally test this using the CEP-based approach, similar experiments were
performedbutwithinHeLa, a hypotetraploid cell line (Figure 1D). As above,
eachCEP correctly hybridized to the corresponding pericentric regions of the
cognate chromosomes within mitotic chromosome spreads. More
importantly however, each CEP produced similar focal numbers within
mitotic and interphase cells, four copies of chromosome 8 and three copies
each of chromosomes 11 and 17. Thus, the above data confirm that CEP8/
11/17 hybridize to the pericentric regions of the correct chromosomes with
high specificity and further validate that each probe can successfully be
employed to enumerate chromosomes within interphase cells.
Clinical and Physical Characteristics of the I-CRC and
Sporadic CRC Samples
The cohort comprised a 2:1 ratio of sporadic (control) to I-CRC
samples (95 sporadic CRCs to 46 I-CRCs). The characteristics of the
matched cohort are presented in Table 1. Because of matching, the
sex, age, and tumor location distributions were similar between the) P
Value ‡
Combined CIN (N = 116) CRC Cohort CIN-Negative (N = 22) P
Value
n (%) n (%)
.69 69.8 ±8.1 72.2 ± 7.1 .18
.71 74 (81.3) 17 (18.7) .33
42 (89.4) 5 (10.6)
.84 82 (80.4) 20 (19.6) .06
34 (94.4) 2 (5.6)
.78 0 1 (100.0) .24
17 (100.0) 0
35 (72.9) 13 (27.1)
36 (85.7) 6 (14.3)
27 (93.1) 2 (6.9)
1 (100.0) 0
.86 52 (80.0) 13 (20.0) .23
63 (88.7) 8 (11.3)
.72 7 (77.8) 2 (22.2) .23
85 (87.6) 12 (12.4)
13 (65.0) 7 (35.0)
1 (100.0) 0
10 (90.9) 1 (9.1)
.62 92 (86.8) 14 (66.7) .047
14 (13.2) 7 (33.3)
.45 76 (70.4) 12 (66.7) .78
.04 37 (88.1) 5 (11.9) .60
69 (83.1) 14 (16.9)
x colonoscopy are based on the percentage of the reviewed cases. The number of colonoscopies performed by
protect anonymity of the data.
Table 2. Results of CIN Analysis
Total N* Sporadic CRC
(n †, %)
Total N I-CRC
(n, %)
P Value ‡
CIN-positive 94 80 (85.1) 44 36 (81.8) .63
Sex
Female 30 28 (93.3) 17 14 (82.4) .34
Male 64 52 (81.3) 27 22 (81.5) 1
Age, mean ± SD 80 69.9 ± 8.0 36 69.6 ± 8.2 .87
Tumor location
Proximal colon 69 57 (82.6) 33 25 (75.8) .43
Distal colon 25 23 (92.0) 11 11 (100.0) 1
TNM stage
0 0 0 1 0
1 11 11 (100.0) 6 6 (100.0) 1
2 34 25 (735) 13 10 (76.9) 1
3 28 25 (89.3) 15 11 (73.3) .22
4 20 18 (90.0) 9 9 (100.0) 1
N/D§ 1 1 (100.0) 0 0
TNM stage (clustered)
1 and 2 45 36 (80.0) 19 16 (84.2) .74
3 and 4 48 43 (89.6) 24 20 (83.3) .47
Grade
1 7 5 (71.4) 2 2 (100.0) 1
2 67 59 (88.1) 30 26 (86.7) 1
3 13 9 (69.2) 7 4 (57.1) .65
4 1 1 (100.0) 0 0
Unknown 6 6 (100.0) 5 4 (80.0) .45
Grade (clustered)
1 and 2 74 64 (86.5) 32 28 (87.5) 1
3 and 4 14 10 (71.4) 7 4 (57.1) .64
CIN-negative 94 14 (14.9) 44 8 (18.2) .63
Age, mean ± SD 14 71.1 ± 7.9 8 74.1 ± 5.3 .36
* N = total number of samples in the cohort.
† n = number of samples in a subcategory.
‡ P value b .05 is statistically significant.
§ N/D = not determined.
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distribution were also similar in the two groups. While tumor grade
was less evenly distributed, the two cohorts were well matched with
80% to 85% of each cohort grade 1 or 2. Late-stage (stage 3 and 4)
sporadic tumors were more likely to express CIN phenotype than
early-stage (stage 1 and 2) sporadic tumors (Table 2). There was no
significant difference in the colonoscopy completion rate between the
two groups. The quality of the bowel preparation was recorded in
only one third of the entire cohort, with no significant differences
between the two groups (data not shown). However, a larger
proportion of index colonoscopies were performed by gastroenterol-
ogists for the control group than for the I-CRC group.
Chromosome Instability Is Frequently Observed within I-CRCs
To assess CIN within the sporadic and I-CRCs, gains and/or losses
in chromosomes 8, 11, and 17 were evaluated using the CEP protocol
detailed in Materials and Methods section. Briefly, samples were
hybridized with CEP8/11/17, 3D images were acquired and
deconvolved, and CEP foci were manually enumerated from only
intact nuclei. Whenever possible, 100 nuclei per core were evaluated
from each patient sample, which was cored in duplicate (i.e., 200
nuclei per tumor sample) to address reproducibility (Supplementary
Table 1). Due to the mathematical negating properties of averaging
gains and losses in chromosome numbers within a given sample, a CS
(see Materials and Methods section) was devised, which was
calculated for each individual CEP and all three CEPs combined
(CSC). In essence, a CS is a metric used to describe both the gains and
losses in chromosome numbers (Supplementary Figure 2) within a
given tumor sample, so that comparisons can be made betweensamples and conditions (i.e., I-CRC and sporadic CRC). For
reference purposes, CSC = 0 indicates that the nucleus is diploid
(i.e., harbors two copies of each CEP), while CSC N 0 identifies
increases in gains and losses of chromosome(s). In addition, an overall
mean CS (CS) can be calculated for a given sample or condition (e.g.,
sporadic CRC vs I-CRC, male vs female, proximal vs distal) by
averaging the individual CS values for that condition.
Overall, the distributions of CS values were similar, albeit with a
1.3-fold larger range within the I-CRC samples (0.61-4.61; total
range 4.0) compared to the sporadic samples (0.84-3.87; total range
3.03; Figure 2A). Furthermore, the overallCS values (±SD) were
statistically indistinguishable (P value = 1.0) between the sporadic
CRC (2.28 ± 0.59) and I-CRC (2.28 ± 0.74) samples (Supplemen-
tary Table 2). Due to the general observation that 85% of
non-hereditary CRCs exhibit CIN [23,33], we identified the 15th
percentile from the CS values within the sporadic population (CS =
1.68) and set this as the minimum threshold value required to define
CIN-positive tumors (85% CIN or 80/94 sporadic CRC samples).
Using this threshold, 82% (36/44) of the I-CRCs were classified as
CIN-positive tumors (Figure 2B and Table 2). Collectively, these data
show that I-CRCs and sporadic CRCs share similar gains and losses in
chromosomes 8, 11, and 17.
Evaluating CIN in Sporadic and I-CRCs, Stratified by Sex,
Tumor Location, and Age
Recent studies in sporadic CRCs have shown that MSI occurs
more frequently within females than males. To determine if a similar
distribution occurs with CIN, the CS values calculated were grouped
according to sex (Figure 2C and Supplementary Table 3). Although
theCS values were statistically insignificant for sporadic and I-CRCs
within a given sex, overall they were slightly increased within females
compared to males. The overallCS values for male sporadic and
I-CRCs are 2.23 ± 0.63 and 2.23 ± 0.75, respectively (P value = .98),
while for females they are 2.40 ± 0.48 and 2.37 ± 0.74, respectively
(P value = .87). When evaluating the prevalence of CIN within males
and females using the CS threshold value (1.68) identified above,
there was an increase in the proportion of CIN-positive sporadic
tumors (93%) relative to the I-CRCs (82.4%) among females
(Figure 2D), while males exhibited similar frequencies in both
sporadic CRCs (81%) and I-CRCs (82%). Thus, our data indicate
that CIN is more prevalent within female sporadic tumors than
within female I-CRCs. Surprisingly however, the current data show
that the high prevalence of CIN-positive tumors is not maintained
within the female interval tumors but rather is similar to those
observed in male sporadic and interval tumors.
Previous studies have shown that the prevalence of CIN correlates
with location and that CIN occurs less frequently within the proximal
colon than the distal colon [34–37]. To examine this within I-CRCs,
theCS values from all tumors were classified into one of five locations
from the proximal and distal colon (Figure 2E). With the exception of
the sporadic CRCs isolated from the caecum, a general trend emerged
where the overall CS values increased as the tumor site moved from
the proximal to the most distal colonic regions (P value = .003 from
median test; Supplementary Table 4), and this trend was conserved
within the I-CRCs (P value = .05). In agreement with previous
literature [34–37], the frequency of CIN-positive sporadic tumors
(Figure 2F) was greater within the distal colon (92%; n = 25) than
those in the proximal colon (83%; n = 69). Interestingly, this
difference was conserved within the interval tumors; however, it was
Figure 2. The prevalence of CIN within sporadic and I-CRCs. (A) Scatterplot depicting the distribution of the CS for each sporadic and
I-CRC sample. An overall group meanCS± SD is indicated by the horizontal bars for both the sporadic and interval populations. (B) Bar
graph depicting the percentage of sporadic and I-CRCs displaying a CIN phenotype (black) as defined by CS≥ 1.68 (see Materials and
Methods section). Numbers at the base of the bars identify the total number of samples within that group. (C) Scatterplot depicting the
distribution of CS for males and females within the sporadic and I-CRCs. An overall group meanCS ± SD is indicated for both the sporadic
and interval populations. (D) Bar graph presenting the percentage of male and female tumors exhibiting a CIN phenotype (CS ≥ 1.68;
black). Numbers in each column identify the total number of samples within that group. (E) Scatterplot showing the overall distribution of
CS based on the indicated location (x-axis). An overall group meanCS ± SD is indicated for each location. Note that, in general, the overall
distributions and group means increase from left to right (proximal to distal colon). (F) Bar graph presenting the percentage of sporadic
and I-CRCs exhibiting CIN phenotypes within the proximal and distal colon.
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was 76% (n = 33) and 100% (n = 11) in the distal colon. These data
show that similar trends are observed for both the sporadic and
I-CRCs, where CIN-positive tumors are observed more frequently
within the distal colon rather than the proximal colon.
MSI presents most frequently within the proximal colon of sporadic
CRCs and ismore common in females and elderly patients [1,38].Due to
the general observation thatMSI andCIN aremutually exclusive [23,24],
we predicted that CIN-negative tumors (i.e.,CS values b1.68) would
occur more frequently within the proximal colon of older patients (i.e.,
N65 years). TheCS values decreased with increasing age (P value = .04).
Despite the limited sample sizes, the distribution of CIN-negativetumors within the proximal colon was preferentially associated with older
age in sporadic and I-CRCs (Figure 3A). More specifically, 83.3% (10/
12) of CIN-negative sporadic CRCs and 88% (7/8) of CIN-negative
I-CRCs occurred within individuals N65 years of age. Furthermore, when
all proximal tumors were subclassified based on age greater or lower
than 65 (Figure 3B), a decrease in the frequency of CIN-positive (or an
increase in the CIN-negative) tumors was observed within the older
population (N65 years of age). Collectively, these data show that
CIN-positive tumors from the proximal colon preferentially occur within
younger patients (≤65 years), while CIN-negative tumors are more
prevalent within older patients (N65 years of age) for both sporadic and
interval tumors.
Figure 3. CIN-negative tumors are correlated with age, but not sex, in the proximal colon. (A) Scatterplots depicting the distribution of the
CS values versus age for the proximal sporadic (left) and proximal interval (right) CRC samples. Samples with CS ≥ 1.68 are defined as
CIN-positive (black), while those b1.68 are CIN-negative (white). (B) Bar graphs depicting the prevalence of CIN (black) within sporadic and
interval tumors based on age. The sample size of each group is indicated at the base of each bar.
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Losses of Chromosomes 8, 11, and 17
To determine if any of the three chromosomes evaluated were
preferentially gained or lost from the sporadic or interval tumors, the
chromosome enumeration data were further scrutinized. In brief, the
average gain or loss of each chromosome from each tumor sample was
determined, and the overall population means (±SD) were calculated
for the sporadic and interval cohorts (Supplementary Table 5). As
shown in Figure 4, the overall distribution and the individual CS
values calculated for the gains and losses of each individual
chromosome were similar between sporadic and I-CRCs. In general,
chromosome 8 was preferentially gained (see Supplementary Figure
3), chromosome 17 was preferentially lost, while chromosome 11
exhibited similar losses and gains in both sporadic and I-CRCs
(Supplementary Table 5).
Discussion
In this study, we established, validated, and employed a multiplexed
CEP-based approach to evaluate numerical CIN within a Manitoban
cohort of CRCs comprising 95 sporadic and 46 interval tumors.
Using cell-based models, we confirmed the specificity of each CEP
and subsequently validated their ability to accurately enumerate their
respective chromosomes in mitotic and interphase populations from
both diploid and hypotetraploid cells and applied this approach to
evaluate CIN within sporadic and I-CRCs. To accurately assess
numerical CIN, we developed a novel metric, CS, to describe the
gains and losses in CEP signals in a given tumor or population. This
approach was used to assess numerical CIN, and thus any sampleexhibiting structural CIN, such as balanced translocations, is not
expected to be identified by this approach. To our surprise, the
prevalence of CIN was statistically indistinguishable between the
sporadic and I-CRCs, regardless of how the data was analyzed
(Figure 2). More specifically, the overall distribution and mean CS
values were not statistically different (P value N .05), while they were
similar within male and female sporadic and I-CRC samples, and only
slightly elevated within the female population relative to the male
population. Moreover, a predominant proportion of both sporadic
(85%) and interval (82%) tumors exhibited CIN phenotypes.
However, when the data were grouped according to sex, the
frequency of CIN within female interval tumors (82%) was less
than the corresponding sporadic tumors (93%) but similar to the
frequencies observed for sporadic (81%) and interval (82%) tumors
from males. When analyzed based on location, similar trends were
observed within the sporadic and interval tumors. For example,
increases in mean CS values and the proportion of CIN-positive
tumors increased as the sites transitioned from the proximal to distal
colon. Collectively, these data show that I-CRCs frequently exhibit
gains and losses in chromosomes 8, 11, and 17 and further show that
a predominant proportion (82%) harbors a CIN phenotype.
Advancements in the field of molecular pathologic epidemiology
can be exploited to assess the contribution of environmental factors to
the development of I-CRCs compared to sporadic CRCs.
Before the current study, only two I-CRC cohorts had been
studied, and only with respect to the prevalence of MSI and CIMP,
CIN had yet to be investigated [14,15,17]. The current study was
devised to address this need and facilitate the comparison of CIN
Figure 4. Comparing the gains and losses in chromosome
numbers in I-CRC and sporadic CRC tumors. Scatterplots depicting
the average gain and loss of chromosomes 8 (A), 11 (B), and 17 (C)
in the I-CRC and sporadic CRC samples. The mean and SDs are
indicated and are comparable between the I-CRCs and sporadic
CRCs for all chromosome gains and losses.
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carefully selected to include a diverse array of I-CRCs (e.g., location,
gender, and age) to ultimately provide a more complete understand-
ing of these tumors in general. A critical component of this study was
the criteria employed to define and identify the I-CRC to be
evaluated. Conceptually, too long of an interval after colonoscopy
could erroneously include sporadic tumors that develop throughtraditional pathways, while too short of an interval could inadver-
tently include sporadic tumors whose date of diagnosis was delayed
due to delays in processing and reporting of pathology specimens
[18]. Thus, our study restricted the analyses of I-CRCs to those
diagnosed 6 to 36 months following a colonoscopy. We excluded
CRCs diagnosed between 1 and 6 months from both groups (I-CRCs
and sporadic CRCs) to avoid misclassification. Importantly, the
I-CRC samples were matched to control sporadic CRC samples in a
1:2 ratio with respect to age, sex, and tumor location to avoid the
potential differences in these characteristics among the CRCs from
affecting the CIN analysis.
Although CIN has previously been evaluated using traditional
cytogenetic approaches involving mitotic spreads, it is rarely
investigated within interphase cells and has never been evaluated
within I-CRCs. Accordingly, a major goal of the current study was to
develop and validate a novel approach to evaluate CIN by examining
the gains and losses in three chromosomes within interphase cells,
which represent the predominant (N99%) cellular population within
solid tumor samples (McManus and Cisyk, personal observation).
Thus, it is critical to compare the results we obtained to those from
previous studies involving sporadic CRCs. Overall, the CIN results
and observations we made are in agreement with those of numerous
other studies. For example, our approach identified an increase in the
prevalence of CIN in sporadic tumors isolated from distal colon
relative to the proximal colon, which is in agreement with those of
Reichmann et al. [34] and Delattre et al. [35]. Furthermore, late stage
sporadic tumors within the current study exhibited an increase in
CIN (Table 2) and are consistent with previous work showing that
CIN correlates with advance stage disease and poor prognosis
[36,39,40]. Thus, the in situ CEP-based approach employed on
interphase cells in this study accurately detects known trends within
the sporadic samples and strongly supports its use in the
characterization of CIN within the I-CRCs.
Through our analysis of the Manitoba cohort of I-CRCs and
sporadic CRCs, we have identified the relative prevalence of CIN
within I-CRCs. Specifically, 82% of I-CRCs were identified as
exhibiting a CIN phenotype, a slightly lower (although not
significantly different) prevalence compared to 85% of sporadic
CRCs. Within sporadic CRC, MSI and CIN are often considered to
be mutually exclusive pathways, and it has been proposed that CIMP
may contribute to the development of either MSI or CIN.
Importantly, previous studies have shown that the MSI phenotype
was about three-fold more prevalent within the I-CRCs (~45%) than
in the corresponding sporadic tumors (~15%) [15,17]. Thus, if MSI
and CIN are in fact mutually exclusive, then it can be expected that
the prevalence of CIN would decrease from ~85% to ~55% within
I-CRCs. However, we failed to detect a significant decrease within the
I-CRCs, as ~82% of tumors still exhibited a CIN phenotype. A
possible explanation for high prevalence of CIN within the I-CRCs is
that they were simply missed during the initial colonoscopy, which
may be due to inaccurate surveillance or distinct clinical phenotype/
features associated with certain polyps and/or tumors (reviewed in
[18]). An alternative possibility is that I-CRCs represent a unique
subset of tumors that harbor both CIN and MSI phenotypes. For
example, it is possible that defects in the CIMP pathway could result
in the epigenetic silencing of critical genes within the CIN and MSI
pathways, which collectively synergize and drive the rapid growth of
I-CRCs. Accordingly, subsequent studies are highly warranted in the
Manitoban cohort, and those in which the initial MSI and CIMP
Neoplasia Vol. 17, No. 3, 2015 Prevalence of Chromosome Instability Cisyk et al. 315work were conducted to concomitantly study the CIN and MSI
pathways in the same cohort [14,15,17].
While our current understanding about the etiological origins of
I-CRCs is limited, the pathways contributing to genomic instability
within these tumors have now been identified. Our study provides
evidence thatCIN is a prevalent aberrant phenotype within I-CRCs and
provides a mechanism for which CIN can be analyzed in many tumor
types. An important strength of the current study is the development of a
novel molecular pathologic approach to assess CIN that can be coupled
with traditional clinical and epidemiological-based data (e.g., age, body
mass index, diet, environmental factors, and so on) in an emerging field
collectively referred to as molecular pathologic epidemiology [41–43].
The goal of molecular pathologic epidemiology is to integrate both
molecular and population-level health information to help identify
causative factors that contribute to the etiology of diseases, such as I-CRC.
Accordingly, this study has developed a new CIN screen that can be
considered an epidemiologic exposure variable, which can now be
incorporated into future molecular pathologic epidemiology studies.
Furthermore, an overall greater understanding of I-CRCs, especially at the
molecular level, may uncover subcategories within I-CRCs, including
missed sporadic CRC, synergistic growth advantage CRCs, and other
contributors that are currently unknown. This evidence should help to
identify precursor lesions andmay impact screening programs with regard
to the recommended time interval between screening colonoscopies. The
ultimate goal is to understand the altered biology of I-CRCs to improve
screening programs and develop novel therapeutic targets.
Appendix A. Supplementary Materials
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.02.001.References
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